Antitumor effects on mouse melanoma elicited by local secretion of interleukin-12 and their enhancement by treatment with interleukin-18

Cancer Investigation

Volumn 18, Issue 3, 2000, Pages 206-213

  Nagai, Hiroshi ^a,c   Hara, Isao ^a   Horikawa, Tatsuya ^a   Fujii, Mitsukiyo ^b   Kurimoto, Masashi ^b   Kamidono, Sadao ^a   Ichihashi, Masamitsu ^a  

^a KOBE UNIVERSITY   (Japan)

^b HAYASHIBARA BIOCHEMICAL LABORATORIES INC   (Japan)

^c KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 12; RECOMBINANT INTERLEUKIN 18;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; HISTOPATHOLOGY; INFLAMMATORY INFILTRATE; LEUKOCYTE COUNT; MELANOMA; MELANOMA B16; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION;

EID: 0034105411     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357900009031825     Document Type: Article

References (22)

1. Kobayashi M, Fitz L, Ryan M, et al: Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biological effects on human lymphocytes. J Exp Med 170:827-845, 1989.
2. Stern AS, Podiaski FJ, Hulmes JD, et al: Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. Proc Natl Acad Sci USA 87:6808-6812, 1990.
3. Gately MK: Interleukin-12: a recently discovered cytokine with potential for enhancing cell-mediated immune responses to tumors. Cancer Invest 11:500-506, 1993.
4. Trinchieri G: Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 84:4008-4027, 1994.
5. Brunda MJ, Luistro L, Warrier RR, et al: Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 178:1223-1230, 1993.
6. Cohen J: IL-12 deaths: explanation and a puzzle. Science 270: 908, 1995.
7. Tahara H, Zeh HJ III, Storkus WJ, et al: Fibloblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res 54:182-189, 1994.
8. Martinotti A, Stoppacciaro A, Vagliani M, et al: CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes. Eur J Immunol 25:137-146, 1995.
9. Fidler IJ: Selection of successive tumor lines for metastasis. Nature 242:148-149, 1973.
10. Okamura H, Tsutsui H, Komatsu T, et al: Cloning of a new cytokine that induce IFN-γ production by T cells. Nature 378:88-91, 1995.
11. Micallef MJ, Ohtsuki T, Kohno K, et al: Interferon-γ-inducing factor enhances T helper 1 cytokine production by stimulated human T cells: synergism with interleukin-12 for interferon-γ production. Eur J Immunol 26:1647-1651, 1996.
12. Micallef MJ, Yoshida K, Kawai S, et al: In vivo antitumor effects of murine interferon-γ-inducing factor/interleukin-18 in mice bearing syngeneic Meth A sarcoma malignant ascites. Cancer Immunol Immunother 43:361-367, 1997.
13. Okayama H, Berg P: A cDNA cloning vector that permits expression of cDNA inserts in mammalian cells. Mol Cell Biol 3:280-289, 1983.
14. Miller J, Germain RN: Efficient cell surface expression of class II MHC molecules in the absence of associated invariant chain. J Exp Med 164:1478-1489, 1986.
15. Sambrook J, Fritsch FF, Maniatis T: Molecular cloning, Cold Spring Harbor, Cold Spring Harbor Laboratory Press, 1982, pp. 33-36.
16. Southern PJ, Berg S: Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter. J Mol Appl Genet 1:327-341, 1982.
17. Gately MK, Chizzonite R: Measurement of human and mouse interleukin 12. In: Current Protocols in Immunology, Vol. 1, edited by JE Coligan, AM Kruisbeek, DH Margulies, EM Shevach, W Strober, New York, John Wiley & Sons Inc., 1992, pp. 1-18.
18. Dranoff G, Jaffee E, Lazenby A, et al: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90:3539-3543, 1993.
19. Fearon ER, Pardoll DM, Itaya T, et al: Interleukin-2 production by tumor cells bypasses T-helper function in the generation of an anti-tumor response. Cell 60:387-403, 1990.
20. Hara I, Nguyen H, Takechi Y, et al: Rejection of mouse melanoma elicited by local secretion of interleukin-2: implicating macrophages without T cells or natural killer cells in tumor rejection. Int J Cancer 61:253-260, 1995.
21. Tsutsui H, Nakanishi K, Matsui K, et al: Interferon-γ-inducing factor (IGIF) upregulates Fas-ligand mediated cytotoxic activity of murine natural killer cell clones. J Immunol 157:3967-3973, 1996.
22. Dao T, Ohashi K, Kayano T, et al: Interferon-γ-inducing factor, a novel cytokine, enhances Fas ligand-mediated cytotoxicity of murine T helper 1 cells. Cell Immunol 173:230-235, 1996.